Global Liver Institute Offering Multilingual Materials and Grants for International NASH Day on June 10
March 04, 2021 09:24 ET
|
Global Liver Institute
Washington, DC, March 04, 2021 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI) is pleased to announce that the 2021 International NASH Day (#NASHday) will be held on June 10, 2021, with the theme,...
Surrozen Awarded NIH Grant to Support Development of SZN-043, a Liver-Specific Regenerative Antibody, for the Treatment of Severe Alcoholic Hepatitis
October 15, 2020 07:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, has been awarded an NIH grant to...
Surrozen Announces Publication of Second Antibody Platform Technology in Scientific Reports
August 19, 2020 10:00 ET
|
Surrozen, Inc.
-- Novel approach to creating R-spondin-mimetics establishes proof-of-concept for targeted regenerative antibodies -- SOUTH SAN FRANCISCO, Calif., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc.,...
UPDATE -- Surrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical Trials
June 19, 2020 10:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the successful...
Surrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical Trials
June 19, 2020 07:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the successful...
Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development Programs
January 25, 2018 08:30 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat non-alcoholic steatohepatitis...
Galectin Therapeutics to Webcast Corporate Update at Annual Meeting of Shareholders
December 11, 2017 09:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will...
Galectin Therapeutics Announces Results from Phase 2b NASH-CX Trial
December 05, 2017 08:15 ET
|
Galectin Therapeutics Inc.
Statistically significant and clinically meaningful effects observed in NASH cirrhosis patients without esophageal varices treated with GR-MD-02 Conference Call at 8:30 A.M. ET to Present Top Line...
Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update
November 07, 2017 08:15 ET
|
Galectin Therapeutics Inc.
All 52 weeks of infusions and 100% of the doses have been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial Top Line Results of NASH-CX Phase 2b Clinical Trial Expected to be...
Galectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis
October 20, 2017 08:30 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Raj...